Proove Responds To Inaccurate Stories From STAT News And Yesterday's Related Federal Document Subpoena And Search Warrant

IRVINE, Calif., June 8, 2017 /PRNewswire/ -- Yesterday, federal agents came to the Irvine, California office of Proove Biosciences to serve a subpoena and execute a search warrant solely related to the collection of documents.  This action was initiated by the U.S. Attorney's office in the Southern District of California in San Diego.  In the spirit of full cooperation, we have accommodated their requests.  Despite some of the media coverage of this event, there was no "raid", nor have there been any "arrests" or "indictments" issued.  We will continue to cooperate with any future requests for information from the government.

Over the past 6 months, Proove has been subject to a handful of inaccurate stories initiated by STAT News that we believe have contributed to this latest action.  While we originally chose not to dignify these outlandish accusations with a response, we now understand that we can no longer ignore these false stories based on unreliable sources, and filled with erroneous accusations.  We will now respond to these many errors and misstatements promulgated by STAT News and spread by a few disgruntled former employees and consultants.  Proove is confident that the facts supported by verifiable and reliable sources will clearly restore our reputation.

Click here to read Proove's official response to the STAT News articles.

Proove would like to express our appreciation to the federal agents involved in this process yesterday for their professionalism, kindness, and efforts to minimize the impact on our very important, life-saving business operations. 

Today, Proove has resumed full-scale business operations delivering its medically-necessary precision medicine technology which has demonstrated in both 7 years of clinical experience, as well as extensive peer-reviewed published evidence to help clinicians accurately identify patients at risk for opioid abuse with up to 97% accuracy to reduce the opioid abuse epidemic, as well as improve treatment outcomes for patients suffering from our nation's most prevalent and expensive health condition – chronic pain. 

For more information about Proove or to request an interview to learn the truth about Proove's technology and its business practices, please visit our web site or contact Cindy Felicicchia at [email protected].  

About Proove® Biosciences: Proove^® Biosciences is the leader in precision medicine for the condition that lies at the nexus of health – pain.  Proove® delivers precision medicine solutions for the nation's most prevalent and expensive health condition by investing heavily in research that has won awards from leading medical societies and been published in peer-reviewed journals.  Discovered by NIH-funded scientists, Proove^® has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk. Proove®'s medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions.  Positioned as The Healthcare Decision Company,™ Proove^®'s patented technology platform combines genetic, clinical, environmental and lifestyle information to help clinicians better evaluate pain sensitivity, assess risk for opioid use disorder, predict therapeutic response to pain medications, and assess drug metabolism for the many medications used in chronic pain patients.  Based in Irvine, California, Proove^® has been recognized on the Inc. 500 and the Deloitte Technology Fast500 as one of the fastest growing companies in North America.   For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

SOURCE Proove Biosciences, Inc.

Related Links

http://proove.com